NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
51 trialsNCT07476794 2026-03-17
TEMPO
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT05463848 2026-03-04
Surgical Pembro +/- Olaparib w TMZ for rGBM
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05607407 2026-03-04
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06319027 2026-03-02
GABLE
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06805305 2026-02-23
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
Phase 2 Recruiting
NCT04765514 2026-02-13
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT07225621 2026-02-05
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
NCT05653622 2026-02-04
SIB-DOPA
Centre Paul Strauss
Phase 2 Recruiting
NCT02394626 2026-02-02
RESURGE
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT07364786 2026-01-23
AFGBMBiop
Skane University Hospital
Phase 2 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05465954 2026-01-12
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
Phase 2 Recruiting
NCT05871021 2026-01-09
PRIDE
University Hospital Tuebingen
Phase 2 Recruiting
NCT06558214 2026-01-07
OPTIMUS PRIME
University of Florida
Phase 2 Recruiting
NCT05708352 2025-12-24
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT05052957 2025-11-21
hSTAR GBM
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT02977780 2025-11-10
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07193654 2025-09-26
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06649851 2025-09-25
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital
Phase 2 Recruiting
NCT06835803 2025-09-18
ELITE-GBM
Brigham and Women's Hospital
Phase 2 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT07003542 2025-08-11
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06356883 2025-08-07
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
Phase 2 Recruiting
NCT04559230 2025-08-05
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT05929495 2025-07-25
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
University of Milano Bicocca
Phase 2 Recruiting
NCT04523688 2025-07-22
Combi G-Vax
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04765098 2025-06-26
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT06598787 2025-05-07
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06936046 2025-04-20
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06016452 2025-04-11
CHROME
Tata Memorial Centre
Phase 2 Recruiting
NCT02800486 2025-04-09
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT06710249 2025-01-27
AFBTEdema
Skane University Hospital
Phase 2 Recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting
NCT05565521 2024-12-02
UNITED2
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT04267978 2024-10-15
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
Phase 2 Recruiting
NCT06595186 2024-09-19
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
Phase 2 Recruiting
NCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Recruiting
NCT06327451 2024-03-25
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Tianjin Medical University General Hospital
Phase 2 Recruiting
NCT06297512 2024-03-07
Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).
Meyer Children's Hospital IRCCS
Phase 2 Recruiting